Overview

• Switzerland-based gene editing firm's Q4 revenue missed analyst expectations

• Net loss for Q4 widened significantly compared to the same period last year

• Company highlighted progress in clinical and preclinical programs across its portfolio

Outlook

• CRISPR Therapeutics expects pediatric regulatory submissions for CASGEVY in H1 2026

• Company anticipates updates on CTX310 and CTX611 trials in H2 2026

• CRISPR Therapeutics plans to initiate CTX460 clinical trial in mid-2026

Result Drivers

• CASGEVY GROWTH - CRISPR Therapeutics reported nearly three-fold increase in patient initiations and first cell collections for CASGEVY in 2025 compared to 2024, indicating strong demand

• COLLABORATION EXPENSE - Increased to $53.7 mln from $10.4 mln a year ago, impacting operating expenses

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for CRISPR Therapeutics AG is $74.00, about 53.1% above its February 11 closing price of $48.32

Press Release: ID:nGNXb898DB

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)